Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

Blood (2025) 146 (Supplement 1): 5350.

https://doi.org/10.1182/blood-2025-5350

Published: 2025

Journal Articles

Impact of frailty in survival of older patients with classical Hodgkin lymphoma: A retrospective, multicenter study from the spanish registry of lymphoma (RELINF) of the spanish group of lymphoma (GELTAMO)

Raul Cordoba, Maria Carmen Martinez Munoz, Rosa Maria Rodriguez Nunez, Blanca Sánchez-González, Miriam Moreno, Norma Gutiérrez, David Alonso Castronuño, Jimena Cannata, Pilar Gomez Prieto, Laurentino Benito, Tamara Torrado, Joan Buch, Juan Carlos Caballero, Nazaret Dominguez, Raquel Santiago Alonso, Isabel González-gascón-y-Marín, Maria Moya Arnao, Beatriz De La Cruz, Cecilia Carpio, Maria Dolores Gutiérrez-Meca Maestre, Luis Antonio López Gómez, Eukene Gainza, Maria Rocio Figueroa Mora, Paula Fernandez-Caldas, Mariana Bastos-Oreiro, Paola Villafuerte Gutiérrez, Samuel Romero Dominguez, Belen Navarro Matilla, Izaskun Zeberio, Emilia Pardal De La Mano, Antonio Gutierrez, Eva Donato, Javier Nuñez, Teresa Cobo, Begona Mendibil, Inigo Olazabal Eizaguirre, Maria Isabel Gomez Roncero, Cristina Barrenetxea, Haridian de la Nuez, Sara Ferrero, Roberto Trelles, Maria Garcia Roa, Luis Ignacio Sancho Val, Sofia Martin-Consuegra, Maria Luisa Bengochea, Carmen Alonso Prieto, Elena Ramila, Hugo Daniel Luzardo Henríquez, Maria Jesus Peñarrubia, Alfonso Ortiz, Ignacio Mahillo, Eva Domingo Domenech

Blood (2025) 146 (Supplement 1): 6264.

https://doi.org/10.1182/blood-2025-6264

Published: 2025

Journal Articles

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Blood (2025) 146 (Supplement 1): 899.

https://doi.org/10.1182/blood-2025-899

Published: 2025

Journal Articles

Real-world outcomes and prognostic factors in older adults with early-stage classic Hodgkin lymphoma: A study from the spanish relinf-geltamo registry

Blood (2025) 146 (Supplement 1): 3621.

https://doi.org/10.1182/blood-2025-3621

Published: 2025

Journal Articles

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Blood (2024) 144 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2024-212008

Published: 2024

Journal Articles

Liposomal Doxorubicin in Aggressive B Cell Lymphoma Has Similar Efficacy to the Conventional Formulation: Results from a Retrospective Cohort Study

Evelyn Acuña Cruz, MD, Jimena Cannata Ortiz, MD, Ana García-Noblejas, MD, Adrian Alegre, Reyes Arranz Sáez, MD

Blood (2015) 126 (23): 5106.

https://doi.org/10.1182/blood.V126.23.5106.5106

Published: 2015

Journal Articles

Outcome and Long Term Toxicity of the LNH- PRO Trial after 12 Year Median Follow-up, in Patients with Indolent Non Hodgkin's Lymphoma Who Received Immunochemotherapy with CVP and Interferon-alfa2b (IFNα2b)

Jimena Cannata-Ortiz, MD, Concepción Nicolás, MD, Ana García-Noblejas, MD, Javier Lopez, Pilar Sabin, Pilar Zamora, Maria José Requena, Reyes Arranz, MD PhD

Blood (2014) 124 (21): 4465.

https://doi.org/10.1182/blood.V124.21.4465.4465

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)

Blood (2014) 124 (21): 3980.

https://doi.org/10.1182/blood.V124.21.3980.3980

Published: 2014

Journal Articles

Peripheral T/NK-Cell Lymphomas: Survival with Current Treatment Strategies. La Princesa University Hospital Single Experience

Miriam González-Pardo, Carlos Fernández-Arandojo, Jimena Cannata, Beatriz Aguado, Ana García-Noblejas, MD, Adrian Alegre, Reyes Arranz, MD PhD

Blood (2014) 124 (21): 5897.

https://doi.org/10.1182/blood.V124.21.5897.5897

Published: 2014

Journal Articles

Clinical and Biological Prognostic Factors Evaluation of Diffuse Large B-Cell Lymphoma Patients Relapsed or Refractory After Previous Line with Rituximab Plus Chemotherapy. Results of the Study PRO-R-IPI (NCT01369784),

Blood (2011) 118 (21): 3654.

https://doi.org/10.1182/blood.V118.21.3654.3654

Published: 2011

Journal Articles

Bendamustine for Mantle Cell Lymphoma: Retrospective Analysis of the Spanish Experience

Ana García-Noblejas, MD, Belén Navarro Matilla, MD, Carolina Da Silva Rodriguez, Raquel De Oña Navarrete, MD, María José Ramirez Sánchez, MD, Concepción Nicolás, MD, Ricardo Pérez Fernández, Blanca Sanchez Gonzalez, MD, Eva Domingo-Domènech, MD, Jose Javier Sanchez Blanco, MD, Jimena Cannata-Ortiz, MD, Tomás José González-López, MD, Reyes Arranz Sáez, MD, PhD

Blood (2011) 118 (21): 4942.

https://doi.org/10.1182/blood.V118.21.4942.4942

Published: 2011

Journal Articles

The Addition of Rituximab to CVP (Bagley) + Interferon-α as Induction Regimen, Significantly Increases Complete Remission Rates and Progression Free Survival In Intermediate-High Risk Follicular Lymphoma Patients (LNH-pro vs . LNH-pro-05 trial)

Jimena Cannata-Ortiz, Concepción Nicolás, Ana García-Noblejas, Javier Lopez, Maria José Requena, Concepción Alaez, Adrian Alegre, Reyes Arranz

Blood (2010) 116 (21): 2867.

https://doi.org/10.1182/blood.V116.21.2867.2867

Published: 2010

Journal Articles

Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas

Santiago Montes-Moreno, Giovanna Roncador, Lorena Maestre, Nerea Martínez, Lydia Sanchez-Verde, Francisca I. Camacho, Jimena Cannata, Jorge L. Martinez-Torrecuadrada, Yulei Shen, Wing C. Chan, Miguel A. Piris

Blood (2008) 111 (1): 351–358.

https://doi.org/10.1182/blood-2007-06-094151

Published: 2008

Journal Articles

Adult Langerhans’ Cell Histiocitosis (LCH). A Single Institution Experience.

Luis Fayad, MD, Jimena Cannata, MD

Blood (2006) 108 (11): 3890.

https://doi.org/10.1182/blood.V108.11.3890.3890

Published: 2006

Journal Articles

Manteinance Treatment with Interferon (IFN) Is Not Necessary to Achieve Prolonged Progression Free Survival (PFS) in Patients with Indolent Non Hodgkin’s Lymphoma (NHL). Results from a Prospective Randomized Trial on 165 Patients.

Jimena Cannata, Ph, Concepcion Nicolas, PhD, Raul Cordoba Resident, Ph, Consuelo Rayon, PhD, Jose Garcia-Laraña, PhD, Javier Lopez, Ph, Guillermo Perez, Ph, Pedro Sanchez-Godoy, PhD, Pilar Garcia-Alfonso, PhD, Pilar Zamora, Ph, Jose-Maria Fernandez-Rañada, PhD, Reyes Arranz, PhD

Blood (2004) 104 (11): 1392.

https://doi.org/10.1182/blood.V104.11.1392.1392

Published: 2004

Journal Articles

Follicular Lymphoma: Design of a Protein-Based Survival Predictor Using Tissue-Microarrays (TMA).

Francisca I. Camacho, MD, Reyes Arranz-Saez, MD, Alessia Caleo, MD, Jimena Cannata, MD, Laura Cereceda, Leocricia Gonzalez, MD, Mª Elena Perez-Martin, MD, Lydia Sanchez-Verde, PhD, Carlos Montalban, MD, Juan F. Garcia, MD, Miguel A. Piris, MD, Carmen Bellas, PhD

Blood (2004) 104 (11): 2266.

https://doi.org/10.1182/blood.V104.11.2266.2266

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

Impact of frailty in survival of older patients with classical Hodgkin lymphoma: A retrospective, multicenter study from the spanish registry of lymphoma (RELINF) of the spanish group of lymphoma (GELTAMO)

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Real-world outcomes and prognostic factors in older adults with early-stage classic Hodgkin lymphoma: A study from the spanish relinf-geltamo registry

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Liposomal Doxorubicin in Aggressive B Cell Lymphoma Has Similar Efficacy to the Conventional Formulation: Results from a Retrospective Cohort Study

Outcome and Long Term Toxicity of the LNH- PRO Trial after 12 Year Median Follow-up, in Patients with Indolent Non Hodgkin's Lymphoma Who Received Immunochemotherapy with CVP and Interferon-alfa2b (IFNα2b)

Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)

Peripheral T/NK-Cell Lymphomas: Survival with Current Treatment Strategies. La Princesa University Hospital Single Experience

Clinical and Biological Prognostic Factors Evaluation of Diffuse Large B-Cell Lymphoma Patients Relapsed or Refractory After Previous Line with Rituximab Plus Chemotherapy. Results of the Study PRO-R-IPI (NCT01369784),

Bendamustine for Mantle Cell Lymphoma: Retrospective Analysis of the Spanish Experience

The Addition of Rituximab to CVP (Bagley) + Interferon-α as Induction Regimen, Significantly Increases Complete Remission Rates and Progression Free Survival In Intermediate-High Risk Follicular Lymphoma Patients (LNH-pro vs . LNH-pro-05 trial)

Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas

Adult Langerhans’ Cell Histiocitosis (LCH). A Single Institution Experience.

Manteinance Treatment with Interferon (IFN) Is Not Necessary to Achieve Prolonged Progression Free Survival (PFS) in Patients with Indolent Non Hodgkin’s Lymphoma (NHL). Results from a Prospective Randomized Trial on 165 Patients.

Follicular Lymphoma: Design of a Protein-Based Survival Predictor Using Tissue-Microarrays (TMA).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only